lunes, 24 de junio de 2013

Breast Cancer Index Identifies Early Stage E... [Clin Cancer Res. 2013] - PubMed - NCBI

Breast Cancer Index Identifies Early Stage E... [Clin Cancer Res. 2013] - PubMed - NCBI

Clin Cancer Res. 2013 Jun 11. [Epub ahead of print]

Breast Cancer Index Identifies Early Stage ER+ Breast Cancer Patients at Risk for Early and Late Distant Recurrence.


Biostatistics, bioTheranostics, Inc.



Residual risk of relapse remains a substantial concern for hormone-receptor (HR+) positive breast cancer patients, with approximately half of all disease recurrences occurring after 5 years of adjuvant anti-estrogen therapy.


The objective of this study was to examine the prognostic performance of an optimized model of Breast Cancer Index (BCI), an algorithmic gene expression-based signature, for prediction of early (0-5 years) and late (>5 years) risk of distant recurrence in estrogen receptor positive (ER+), lymph node negative (LN-) patients. The BCI model was validated by retrospective analyses of tumor samples from tamoxifen-treated patients from a randomized prospective trial (Stockholm TAM, n=317) and a Multi-institutional cohort (n=358).


Within the Stockholm TAM cohort, BCI risk groups stratified the majority (~65%) of patients as low risk with <3 0-5="" 5-10="" 55="" and="" as="" bci="" beyond="" both="" classified="" clinicopathological="" cohort="" cohorts="" continuous="" distant="" factor="" factors="" for="" had="" in="" larger="" low="" most="" multi-institutional="" of="" patients="" prognostic="" rate="" recurrence="" risk="" significant="" standard="" the="" tumors="" was="" were="" which="" with="" years.="" years="">5 years.


The prognostic sustainability of BCI to assess early and late distant recurrence risk at diagnosis has clinical utility for decisions of chemotherapy at diagnosis and for decisions for extended adjuvant endocrine therapy beyond 5 years.


[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario